Analysis of D Pharm manpower and management performance can provide insight into D Pharm stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with D Pharm LTD future performance. Additionally see Investing Opportunities.
D Pharm Management EffectivenessThe company has return on total asset (ROA) of (42.09) % which means that it has lost $42.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (400.0) % meaning that it generated substantial loss on money invested by shareholders.
D Pharm Workforce Comparison
D Pharm LTD is one of the top stocks in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 22.0. D Pharm totals roughly 11.0 in number of employees claiming about 50% of stocks in Biotechnology industry.
D Pharm Profit MarginsThe company has Profit Margin (PM) of (112.59) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (100.69) % which suggests for every $100 dollars of sales it generated a net operating loss of -1.01.
D Pharm Stakeholders
|Golan Bitton CEO, Director|
|Alexander Kozak Co-Founder, CEO and Pres|
|David Grossman Chairman of the Board|
|Itschak Shrem Chairman of the Board|
|Aharon Schwartz Executive Chairman of the Board|
|Yossi Hatan Vice President - Finance|
|Gilad Rosenberg Vice President Clinical Development|
|Tamar Kfir Director|
|Ofir Shachaf Director|
|Irit Kaufman Independent Director|
|Ronen Rosenbloom Director|
|Nir Zvi Director|
|Assaf Segal Director|
|Ofer Gonen Director|
|Joshua Levine Director|
|Anat Benish External Director|
|Sagi Tamir External Director|
|Sigal Gefen External Director|
|Eli Cohen Director|
|Zohara Ran Independent Director|
|Ofra Yamin VP of Fin. and HR|
|Emanuel Kahane IR Contact Officer|
|Yaron Meyer General Counsel, Secretary|
D Pharm employes about 11 people. The company is managed by 23 executives with total tenure of roughly 92 years, averanging almost 4.0 years of service per executive having 0.0 employee per reported executive.
|Revenue Per Employee||65.7 K|
|Revenue Per Executive||31.4 K|
|Net Loss Per Employee||74 K|
|Net Loss Per Executive||35.4 K|
|Working Capital Per Employee||181.8 K|
|Working Capital Per Executive||87 K|